Expert Review of Vaccines最新文献_第2页

Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus. 打破循环：对水痘-带状疱疹病毒终身疫苗接种战略的考虑。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-19 DOI: 10.1080/14760584.2025.2514527

Giacomo Casabona, Paolo Bonanni, Giovanni Gabutti, Volker Vetter, Maurine Duchenne, Raunak Parikh

{"title":"Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus.","authors":"Giacomo Casabona, Paolo Bonanni, Giovanni Gabutti, Volker Vetter, Maurine Duchenne, Raunak Parikh","doi":"10.1080/14760584.2025.2514527","DOIUrl":"10.1080/14760584.2025.2514527","url":null,"abstract":"Introduction: Varicella-zoster virus (VZV) is a highly contagious virus that manifests as varicella (chickenpox) as primary infection and reactivates as herpes zoster (HZ, shingles), with the potential for severe complications. Vaccines against varicella and HZ are available and highly effective, but recommendations vary between countries.Areas covered: This qualitative review discusses the literature regarding (i) the burden of varicella and HZ; (ii) current approaches to vaccination against VZV-related diseases and reasons why varicella and HZ vaccination may not have been widely implemented, and (iii) real-world evidence and trends from countries with vaccination program experience.Expert opinion: Varicella and HZ pose significant burdens. The availability of effective vaccines with established safety profiles means that prevention of both manifestations of VZV disease is now largely possible. Reasons why National Immunization Technical Advisory Groups may not recommend varicella and HZ vaccination programs include cost-effectiveness, considerations relating to the interplay of both diseases, and low awareness of the true disease burden. Nevertheless, real-world evidence from countries with existing vaccination programs is demonstrating positive impacts of vaccination on disease incidence and cost. Including both varicella and HZ vaccines in National Immunization Programs can be an effective life-course strategy to tackle the burden of VZV-related diseases.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"556-569"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between parental vaccine literacy and their willingness to vaccinate children against influenza in china. 中国父母疫苗素养与儿童接种流感疫苗意愿的关系

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-14 DOI: 10.1080/14760584.2025.2534617

Zhuoran Huang, Ziwen Song, Minjuan Shi, Zhiheng Liao, Lisha Deng, Hongbiao Chen, Jianhui Yuan, Caijun Sun

{"title":"Relationship between parental vaccine literacy and their willingness to vaccinate children against influenza in china.","authors":"Zhuoran Huang, Ziwen Song, Minjuan Shi, Zhiheng Liao, Lisha Deng, Hongbiao Chen, Jianhui Yuan, Caijun Sun","doi":"10.1080/14760584.2025.2534617","DOIUrl":"10.1080/14760584.2025.2534617","url":null,"abstract":"Background: Influenza poses a significant global public health burden, particularly among pediatric populations. However, the coverage of influenza vaccination among Chinese children remains inadequate.Research design and methods: This study explores the relationship between parental vaccine literacy and willingness to vaccinate their children against influenza. A cross-sectional online survey was conducted using an anonymous questionnaire. Vaccine literacy was measured by the Vaccine Health Literacy scale, and logistic regression with mediation analyses was used to identify influencing factors.Results: Among 6,177 participants, 94.67% expressed willingness to vaccinate their children. Higher vaccine literacy, especially interactive vaccine literacy, was positively associated with willingness and mediated key predictors. Male parents (OR = 1.408, p = 0.034) with prior vaccination history (OR = 6.402, p < 0.001) were more likely to vaccinate, while those with younger age (OR = 0.959, p < 0.001) and lower education (OR = 0.587, p < 0.001) were less likely to vaccinate.Conclusions: Our study found that parents' vaccine literacy, particularly interactive vaccine literacy, shows a potential association with their willingness to vaccinate their children against influenza. Targeted interventions aimed at improving parental vaccine literacy and addressing their vaccine hesitancy are critical for enhancing influenza vaccination coverage among children.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"612-622"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE? 欧洲消除宫颈癌和预防人乳头瘤病毒（hpv）相关癌症的准备情况评估——我们是否赢得了竞赛？

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-15 DOI: 10.1080/14760584.2024.2438759

Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby

{"title":"Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE?","authors":"Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby","doi":"10.1080/14760584.2024.2438759","DOIUrl":"10.1080/14760584.2024.2438759","url":null,"abstract":"Introduction: To address the cervical cancer burden globally, the World Health Organization and European Union released strategies to facilitate HPV-related cancers prevention, including cervical cancer elimination. This research assessed European country level readiness to achieve cervical cancer elimination by adhering to such strategies.Areas covered: Readiness for cervical cancer elimination was assessed across a range of guiding questions relevant to three defined key domains: vaccination, screening, and treatment, each with two sub-domains focusing on decision making and implementation efforts. Publicly available data sources were used to inform the scoring across domains, to tier countries into either high, moderate-high, moderate-low, and low readiness archetypes.Key parameters identified associated with the high readiness archetype were high vaccination coverage rates (>70%), availability of gender neutral and catch-up vaccination, school-based vaccination availability, organized screening programs, use of HPV DNA primary screening tests, and data surveillance.Expert opinion: Our analysis highlights significant variability in decision making and implementation of vaccination, screening, and treatment programmes across Europe. Country scores expose the need for a multifaceted approach to achieve cervical cancer elimination in Europe, encompassing solid decision making commitments, implementation of these commitments, and the ability to collect, surveil, and apply the data use accurately.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"11-26"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response. 迈向丙型肝炎疫苗：引发有效b细胞反应的免疫策略概述。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-28 DOI: 10.1080/14760584.2025.2452955

Gabriel L Costa, Giuseppe A Sautto

{"title":"Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response.","authors":"Gabriel L Costa, Giuseppe A Sautto","doi":"10.1080/14760584.2025.2452955","DOIUrl":"10.1080/14760584.2025.2452955","url":null,"abstract":"Introduction: Fifty-eight million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antivirals are highly effective; however, they are burdened by high costs and the unchanged risk of HCC and reinfection, making prophylactic countermeasures an urgent medical need. HCV high genetic diversity is one of the main obstacles to vaccine development. The protective role of the humoral response directed against the HCV E2 glycoprotein is well established, and broadly neutralizing antibodies play a crucial role in effective viral clearance.Areas covered: This review explores the HCV targets and the different vaccination approaches, encompassing different expression systems, antigen selection strategies, and delivery methods, focusing on those aimed at eliciting a broad and effective humoral response. Our search criteria included the keywords 'HCV,' 'Hepatitis C,' and 'vaccine' using publicly available databases. Following the screening, 54 papers were selected.Expert opinion: The investigation of novel vaccine platforms beyond traditional approaches is necessary. While progress has been made in this direction, continued investigations on the HCV virology, immunology, and vaccinology are essential to surmount associated obstacles, heling in the development of an HCV vaccine that can benefit the global public health.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"96-120"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants. 二价蛋白COVID-19疫苗SCTV01C对抗原匹配和不匹配变体的持续免疫原性

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/14760584.2025.2456231

Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie

{"title":"Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.","authors":"Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie","doi":"10.1080/14760584.2025.2456231","DOIUrl":"10.1080/14760584.2025.2456231","url":null,"abstract":"Background: The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.Research design and methods: In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primary series of two doses and a booster dose of SCTV01C, a bivalent protein SARS-CoV-2 vaccine.Results: Geometric mean titers (GMTs) of neutralizing antibodies (nAb) against live Alpha, Beta, Delta, and Omicron showed 85.4-, 100.0-, 32.1-, and 9.8-fold increase from baseline on 28 days, and 49.4-, 55.3-, 5.7-fold increase against live Alpha, Beta, and Omicron on 90 days after primary series. At Day 28 and Day 90 following the booster dose, GMTs of nAb against Beta, BA.2 and BA.5 variants showed 12.1- and 8.8-, 13.8- and 7.1-, 18.7-, and 11.9-fold of increase from baseline, respectively. Reactogenicity was generally mild, with one adverse event of special interest (AESI) and 9 ≥Grade 3 treatment-related adverse events (TRAEs); all recovered within 3 days.Conclusions: SCTV01C, when administered as both a primary series and a booster vaccination, exhibited encouraging sustained immunogenicity against both antigen-matched and antigen-mismatched variants, with no significant safety concerns.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05148091.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"128-137"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States. 美国成年人对肺炎球菌疫苗的了解、态度和看法。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-19 DOI: 10.1080/14760584.2024.2441250

Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier

{"title":"Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.","authors":"Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier","doi":"10.1080/14760584.2024.2441250","DOIUrl":"10.1080/14760584.2024.2441250","url":null,"abstract":"Objectives: The attitudes and perceptions of healthcare consumers (HCCs) are increasingly becoming more relevant in decision-making with healthcare providers and incorporated into healthcare decision-making by national immunization technical advisory groups and health technology assessment agencies. With newer pneumococcal vaccine options available, HCCs' attitudes and perceptions play a key role in gauging potential acceptance. The objective of this study was to assess HCCs' knowledge, attitudes, and perceptions toward pneumococcal vaccines for adults.Methods: Between March and May 2024, eligible U.S. adult HCCs were invited to participate in an online survey focusing on experiences and attitudes toward vaccines.Results: Among 141 participating HCCs, average age was 53.1 years. The majority of participants were male (51.1%) and 64.5% identified as White. Most HCCs received at least one vaccine in the past year (81.6%). HCCs most often received vaccines at medical offices and pharmacies. HCCs supported lowering the age-based pneumococcal vaccine recommendation to all adults 50 years and older and were willing to receive a supplemental pneumococcal vaccine dose following completion of the recommended series for additional protection.Conclusions: These findings indicate that new adult pneumococcal vaccines would be accepted and valued by HCCs if recommended by HCPs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"45-52"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia. 利用沙特阿拉伯王国的适应疫苗对不同COVID-19疫苗接种策略的潜在公共卫生和经济影响进行建模。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-17 DOI: 10.1080/14760584.2024.2438757

Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff

{"title":"Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia.","authors":"Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff","doi":"10.1080/14760584.2024.2438757","DOIUrl":"10.1080/14760584.2024.2438757","url":null,"abstract":"Background: The dynamic evolution of the virus causing COVID-19 necessitates the development of adapted vaccines to protect against emerging variants.Research design and methods: A combined Markov-decision tree model estimated the outcomes of alternative vaccination strategies. The Saudi Arabian population was stratified into standard-risk and high-risk subpopulations, defined as either the population comprising individuals aged ≥ 65 years and individuals with at least one comorbidity. The model estimated the health and economic outcomes of vaccination based on age-specific inputs taken from published sources and national surveillance data.Results: The vaccination strategy targeting the elderly and high-risk subpopulation (was estimated to prevent 156,694 cases 12,800 hospitalizations, and 2,919 deaths and result in cost savings of SAR 1,239 million in direct costs and SAR 4,145 million in indirect costs. These gains increased with the vaccination strategies additionally targeting other subpopulations. Compared to the base case (aged ≥65 and those at high-risk), expanding vaccination coverage to 75% of the standard-risk population prevented more cases (323%), hospitalizations (154%), and deaths (60%) and increased the direct (232%) and indirect (270%) cost savings.Conclusions: The adoption of broad vaccination strategies using a vaccine adapted to the dominant variant in circulation would yield substantial benefits in Saudi Arabia.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"27-36"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The broader socio-economic value of adult respiratory disease vaccinations in the UK - results from a benefit cost analysis. 更广泛的社会经济价值成人呼吸道疾病疫苗接种在英国-结果从效益成本分析。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-22 DOI: 10.1080/14760584.2025.2536093

Cale Harrison, Simon Brassel, Sulayman Chowdhury, Claud Theakston, Matthew Napier, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten

{"title":"The broader socio-economic value of adult respiratory disease vaccinations in the UK - results from a benefit cost analysis.","authors":"Cale Harrison, Simon Brassel, Sulayman Chowdhury, Claud Theakston, Matthew Napier, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten","doi":"10.1080/14760584.2025.2536093","DOIUrl":"10.1080/14760584.2025.2536093","url":null,"abstract":"Background: Respiratory infections such as pneumococcal disease (PD), RSV, influenza (flu), and COVID-19 impose a major socio-economic burden in the UK. Adult vaccination programs cost-effectively reduce this burden, yet their societal value remains under-assessed.Methods: A benefit-cost analysis (BCA) using life-table-based disease modeling estimated morbidity and mortality reductions from current age- and risk-based recommendations. Mortality risk reduction was monetized using two approaches: value of a statistical life year (VSLY) and hence adjusting for remaining life expectancy, and value of a statistical life (VSL), assuming equal valuation across ages. Scenarios included current and expanded eligibility. Outcomes were reported as benefit-cost ratios (BCRs) and net benefits (NBs).Results: Over each cohort's lifetime, vaccinations prevented 313,000 hospitalizations, freed up 1.9 million bed days, and averted over 86,000 deaths. First-year BCRs were 5.1 (VSLY) and 19.3 (VSL), with NBs of £5.1 billion and £23 billion, respectively. Lifetime net benefits ranged from £35.5 billion to £200.1 billion, with BCRs of 5.8 and 27.8. Expanded eligibility further increased NBs but lowered the BCR.Conclusion: Adult respiratory vaccination delivers socio-economic benefits well beyond direct health-care savings, yet investment remains low. Considering broader impacts beyond standard cost-effectiveness can better align policy with public health and economic goals.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"644-655"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity. 广谱冠状病毒疫苗：对抗病毒多样性的综合战略

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-29 DOI: 10.1080/14760584.2025.2538561

Qian He, Yi Zhang, Zhihao Fu, Xiao Ma, Zhenglun Liang

{"title":"Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity.","authors":"Qian He, Yi Zhang, Zhihao Fu, Xiao Ma, Zhenglun Liang","doi":"10.1080/14760584.2025.2538561","DOIUrl":"10.1080/14760584.2025.2538561","url":null,"abstract":"Introduction: The early 21st century witnessed three consecutive public health emergencies caused by Betacoronavirus infections, drawing considerable global attention to the hazards posed by Betacoronaviruses. Vaccines have proved instrumental in mitigating the coronavirus disease 2019 (COVID-19) pandemic, yet the persistent emergence of novel variants underscores the necessity for continuous development of updated vaccines tailored to circulating strains. In addition, new coronavirus outbreaks or the reemerging of previously prevalent coronaviruses may occur in the future.Areas covered: Broad-spectrum coronavirus vaccines, especially pan-coronavirus vaccines, can serve as powerful weapons against known and unknown coronavirus risks. This article presents a comprehensive review of recent advancements in broad-spectrum coronavirus vaccine development, identifies persistent challenges, and outlines strategic directions for vaccine development. It aims to provide essential references and strategic considerations for broad-spectrum or universal coronavirus vaccines.Expert opinion: Prioritizing Betacoronavirus-focused vaccines may provide practical near-term solutions, while long-term success hinges on integrating AI and structural biology for precision engineering. Future efforts must emphasize durable immunity, mucosal strategies, and adaptability to viral diversity. Collaboration across computational, immunological, and virological fields will be essential to achieve universal coronavirus protection.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"1-12"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials. 不同技术平台上5种COVID-19疫苗的不良反应特征：9项临床试验的汇总分析

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-07 DOI: 10.1080/14760584.2025.2502031

Yue Liu, Qian Liu, Lai-Run Jin, Wei-Wei Han, Ming-Wei Wei, Si-Yue Jia, Feng-Cai Zhu, Jing-Xin Li

{"title":"Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials.","authors":"Yue Liu, Qian Liu, Lai-Run Jin, Wei-Wei Han, Ming-Wei Wei, Si-Yue Jia, Feng-Cai Zhu, Jing-Xin Li","doi":"10.1080/14760584.2025.2502031","DOIUrl":"https://doi.org/10.1080/14760584.2025.2502031","url":null,"abstract":"Background: Evidence regarding the comparative safety of different COVID-19 vaccines remains limited. This study aims to characterize and compare the safety profiles of five COVID-19 vaccines in terms of adverse reactions after immunization.Research design and methods: We conducted a retrospective analysis of adverse reactions reported among adults aged 18-59 years from nine clinical trials. The analyzed vaccines included inactivated, recombinant protein, intranasal influenza-vectored, aerosolized and intramuscular Ad5 vectored COVID-19 vaccines. Factor analysis and association rule analysis were used to characterize adverse reaction patterns, while multivariate logistic regression was employed to assess the influence of vaccine type and demographic factors.Results: Inactivated, recombinant, and intramuscular Ad5 vectored vaccines commonly caused injection site pain, fatigue, headache, and pyrexia from the SOC of 'General disorders and administration site conditions.' Intranasal influenza-vectored vaccines mainly cause respiratory symptoms such as rhinorrhea and nasal congestion, while dry mouth and oropharyngeal pain from 'Gastrointestinal disorders' were primarily observed in aerosolized Ad5 vectored vaccines. Younger age (p < 0.001), female sex (p = 0.001), comorbidities (p < 0.001), and intramuscular Ad5 vectored vaccines (p < 0.001) were significantly associated with higher adverse reaction risks.Conclusions: COVID-19 vaccines developed through different technological approaches have distinct adverse reaction profiles.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"339-349"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0